USSN: 10/634,678 Atty. Docket No.: 6888.US.P1 Amendment dated October 13, 2004 Reply to Office Action dated July 20, 2004

# **AMENDMENTS TO THE SPECIFICATION**

## (1) Amendment to the ABSTRACT OF THE DISCLOSURE

Please replace page 236 of the present application with the following page:

## ABSTRACT OF THE DISCLOSURE

Compounds of formula (I)

$$R_{8b}$$
 $X_5$ 
 $X_2$ 
 $X_4$ 
 $R_{8a}$ 
 $X_5$ 
 $X_5$ 
 $X_4$ 
 $X_5$ 
 $X_5$ 
 $X_6$ 
 $X_7$ 
 $X_8$ 
 $X_8$ 

are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$ ,  $X_5$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_{8a}$ ,  $R_{8b}$ ,  $R_9$ ,  $Z_1$ ,  $Z_2$  and L are as defined in the description.

USSN: 10/634,678 Atty. Docket No.: 6888.US.P1 Amendment dated October 13, 2004 Reply to Office Action dated July 20, 2004

#### (2) Amendment to the SUMMARY OF THE PRESENT INVENTION

Please replace paragraph under Formula (I) on page 3, with the following paragraph:

--- or a pharmaceutically acceptable salt or prodrug thereof, wherein

--- is absent or a single bond;

 $X_1$  is selected from the group consisting of N and  $CR_1$ ;

X<sub>2</sub> is selected from the group consisting of N and CR<sub>2</sub>;

X<sub>3</sub> is selected from the group consisting of N, NR<sub>3</sub>, and CR<sub>3</sub>;

X<sub>4</sub> is a bond or selected from the group consisting of N and CR<sub>4</sub>;

 $X_5$  is selected from the group consisting of N and C;

provided that at least one of  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  is N; and provided that when  $X_4$  is a bond, one of  $X_1$ ,  $X_2$ , or  $X_3$  must be NR;

 $Z_1$  is selected from the group consisting of O, NH, and S;

 $Z_2$  is a bond or selected from the group consisting of NH and O;

L is selected from the group consisting of alkenylene, alkylene, alkynylene, ----

#### (3) Amendment to the DETAILED DESCRIPTION OF THE PRESENT INVENTION

(i) Please replace first paragraph on page 5, with the following paragraph:

 $X_1$  is selected from the group consisting of N and  $CR_1$ ;

 $X_2$  is selected from the group consisting of N and  $CR_2$ ;

 $X_3$  is selected from the group consisting of N, NR<sub>3</sub>, and CR<sub>3</sub>;

 $X_4$  is a bond or selected from the group consisting of N and  $CR_4$ ;

X<sub>5</sub> is selected from the group consisting of N and C;

provided that at least one of  $X_1$ ,  $X_2$ ,  $X_3$ , and  $X_4$  is N; and provided that when  $X_4$  is a bond, one of  $X_1$ ,  $X_2$ , or  $X_3$  must be NR;

 $Z_1$  is selected from the group consisting of O, NH, and S;

Z<sub>2</sub> is a bond or selected from the group consisting of NH and O;

L is selected from the group consisting of alkenylene, alkylene, alkynylene,

### (ii) Under "Definition of Terms":

After first two lines of page 26, please add the following paragraphs:

The term "1-azepanyl" as used herein, means a 7-membered ring wherein one of the atoms is nitrogen.

The term "1-azocanyl" as used herein, means a 8-membered ring wherein one of the atoms is nitrogen.